CELLECT BIOTECH/S (NASDAQ:APOP)’s share price was down 3.7% on Wednesday . The company traded as low as $0.51 and last traded at $0.52, approximately 800 shares were traded during mid-day trading. A decline of 100% from the average daily volume of 166,242 shares. The stock had previously closed at $0.54.
Separately, ValuEngine raised shares of CELLECT BIOTECH/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
The business’s 50-day moving average price is $0.52 and its 200 day moving average price is $0.72. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.01 and a quick ratio of 6.01.
A hedge fund recently raised its stake in CELLECT BIOTECH/S stock. Susquehanna International Group LLP grew its position in CELLECT BIOTECH/S (NASDAQ:APOP) by 27.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 97,897 shares of the company’s stock after acquiring an additional 20,949 shares during the period. Susquehanna International Group LLP owned about 0.87% of CELLECT BIOTECH/S worth $50,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.10% of the company’s stock.
About CELLECT BIOTECH/S (NASDAQ:APOP)
Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Featured Article: Debt-To-Equity Ratio
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.